BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
-- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors --
BRISBANE, Calif., May 15, 2008 -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data supporting its lead PARP inhibitor, BSI-201, will be presented at the 2008 American Society of Clinical Oncology annual meeting in Chicago.
Findings will be presented from the first in human Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar will also present a Phase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine, temozolomide and carboplatin/paclitaxel in subjects with advanced solid tumors. The primary objective of these respective studies is to assess the safety profile of BSI-201 when used as a monotherapy and in combination with cytotoxic chemotherapy in subjects with measurable disease.
The schedule of poster presentations is as follows:
Title: |
First in Human Phase 1 Study of BSI-201, a Small Molecule Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with Advanced Solid Tumors |
When: |
Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session |
Title: |
A Phase 1B Study Evaluating BSI-201 in Combination with Chemotherapy in Subjects with Advanced Solid Tumors |
When: |
Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session |
About BiPar Sciences
BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.
Contact:
Eric Malek
Vice President, Corporate Development
650-635-0165
emalek@biparsciences.com
www.biparsciences.com
Stacie D. Byars
WeissComm Partners
206-660-2588
sdbyars@wcpglobal.com